Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | YL211, a c-Met-targeting antibody–drug conjugate, in advanced solid tumors

Michael Cecchini, MD, Yale University, New Haven, CT, discusses dose-escalation results from a first-in-human Phase I study (NCT06384352) of YL211, a c-Met-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, in heavily pretreated patients with advanced solid tumors, the majority with metastatic colorectal cancer. YL211 showed a manageable safety profile comparable to other agents in its class, with mainly hematologic higher-grade toxicities and no interstitial lung disease. Preliminary antitumor activity and high disease control were observed across tumor types, particularly colorectal cancer, supporting continued development. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

YL211 is another cement antibody drug conjugate that is also showing promising results and I think this establishes consistency with the target that there are multiple drugs in this space and there are actually others as well but you know there’s probably some under development but YL211 also showed efficacy in an all solid tumor dose escalation where we established the recommended phase two dose and moved on to actually dose optimization evaluating multiple doses to really confirm those escalation decisions...

YL211 is another cement antibody drug conjugate that is also showing promising results and I think this establishes consistency with the target that there are multiple drugs in this space and there are actually others as well but you know there’s probably some under development but YL211 also showed efficacy in an all solid tumor dose escalation where we established the recommended phase two dose and moved on to actually dose optimization evaluating multiple doses to really confirm those escalation decisions. And in a lung specific cohort demonstrated activity that was impressive and we’re excited for continued development in tumors.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.